Literature DB >> 16148811

Outcome of severe sepsis in pediatric oncology patients.

Richard T Fiser1, Nancy K West, Andrew J Bush, Elaine M Sillos, Jeffrey E Schmidt, Robert F Tamburro.   

Abstract

OBJECTIVE: To describe survival to intensive care unit (ICU) discharge and 6-month survival in a large cohort of pediatric oncology patients with severe sepsis.
DESIGN: Retrospective analysis.
SETTING: The ICU of a single pediatric oncology center. PATIENTS: Patients with cancer admitted to the ICU of St. Jude Children's Research Hospital between January 1, 1990, and December 31, 2002, who met the following criteria: 1) severe sepsis by ACCP/SCCM (American College of Chest Physicians/Society of Critical Care Medicine) Consensus Conference criteria and 2) receipt of fluid boluses of > or =30 mL/kg to correct hypoperfusion or receipt of a dopamine infusion of >5 microg.kg.min for inotropic support.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Data evaluated were demographic variables, oncologic diagnosis and time from diagnosis to ICU admission, Pediatric Risk of Mortality III score and absolute neutrophil count at admission, use of inotropes or pressors, use of mechanical ventilation, maximum organ system failure score, blood culture results, survival to ICU discharge, and 6-month survival. We identified 446 ICU admissions of 359 eligible patients. Overall ICU mortality was 76 of 446 (17%): 40 of 132 (30%) in post-bone marrow transplant (BMT) admissions and 36 of 314 (12%) in non-BMT admissions (p < .0001). In the 106 admissions requiring both mechanical ventilation and inotropic support, ICU mortality was 68 of 106 (64%). Regarding individual patients, 6-month survival was 170 of 248 (69%) among non-BMT patients vs. 43 of 111 (39%) for BMT patients (p < .001). When the 38 patients who survived to ICU discharge after requiring both mechanical ventilation and inotropic/vasopressor support are considered, 27 (71%) were alive 6 months after ICU discharge (22 of 27 [81%] non-BMT vs. 5 of 27 BMT [19%; p < .001]). ICU mortality varied by causative pathogen, from 63% for fungal sepsis (12 of 19) to 9% (5 of 53) for Gram-negative sepsis. Logistic regression analysis of factors significantly associated with ICU mortality in admissions requiring both mechanical ventilation and inotropic support identified four variables: BMT (odds ratio, 2.9; 95% confidence interval, 1.1-7.4; p = .03); fungal sepsis (odds ratio, 10.7; 95% confidence interval, 1.2-94.4; p = .03); use of multiple inotropes (odds ratio, 4.1; 95% confidence interval, 1.4-11.8; p = .01); and Pediatric Risk of Mortality III score (odds ratio, 1.1; 95% confidence interval, 1.0-1.2; p = .04).
CONCLUSIONS: In a large series of pediatric oncology patients with severe sepsis, ICU mortality was only 17% overall, although mortality remained quite high in the higher acuity patients. Mortality among the higher acuity patients was significantly associated with only a small number of variables. The number of patients alive at 6 months and the encouraging ICU survival rate further justifies the use of aggressive ICU interventions in this population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16148811     DOI: 10.1097/01.pcc.0000165560.90814.59

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  24 in total

1.  Hemodynamic changes in the kidney in a pediatric rat model of sepsis-induced acute kidney injury.

Authors:  Kathryn A Seely; Joseph H Holthoff; Samuel T Burns; Zhen Wang; Keshari M Thakali; Neriman Gokden; Sung W Rhee; Philip R Mayeux
Journal:  Am J Physiol Renal Physiol       Date:  2011-04-20

2.  Resveratrol ameliorates sepsis-induced acute kidney injury in a pediatric rat model via Nrf2 signaling pathway.

Authors:  Yan Wang; Fenling Feng; Minna Liu; Jiahong Xue; Huimei Huang
Journal:  Exp Ther Med       Date:  2018-07-27       Impact factor: 2.447

3.  Pediatric cancer type predicts infection rate, need for critical care intervention, and mortality in the pediatric intensive care unit.

Authors:  Matt S Zinter; Steven G DuBois; Aaron Spicer; Katherine Matthay; Anil Sapru
Journal:  Intensive Care Med       Date:  2014-07-15       Impact factor: 17.440

Review 4.  Epidemiology and Outcomes of Pediatric Multiple Organ Dysfunction Syndrome.

Authors:  R Scott Watson; Sheri S Crow; Mary E Hartman; Jacques Lacroix; Folafoluwa O Odetola
Journal:  Pediatr Crit Care Med       Date:  2017-03       Impact factor: 3.624

Review 5.  Specific Etiologies Associated With the Multiple Organ Dysfunction Syndrome in Children: Part 1.

Authors:  Jeffrey S Upperman; Jacques Lacroix; Martha A Q Curley; Paul A Checchia; Daniel W Lee; Kenneth R Cooke; Robert F Tamburro
Journal:  Pediatr Crit Care Med       Date:  2017-03       Impact factor: 3.624

6.  Severe Sepsis-Associated Morbidity and Mortality among Critically Ill Children with Cancer.

Authors:  Salim Aljabari; Alfred Balch; Gitte Y Larsen; Mark Fluchel; Jennifer K Workman
Journal:  J Pediatr Intensive Care       Date:  2018-12-21

7.  Preliminary experience of tigecycline treatment for infection in children with hematologic malignancies.

Authors:  Shupeng Lin; Chenmei Zhang; Sheng Ye
Journal:  Int J Clin Pharm       Date:  2018-07-26

8.  Outcome of pediatric acute myeloid leukemia patients receiving intensive care in the United States.

Authors:  Shannon L Maude; Julie C Fitzgerald; Brian T Fisher; Yimei Li; Yuan-Shung Huang; Kari Torp; Alix E Seif; Marko Kavcic; Dana M Walker; Kateri H Leckerman; Todd J Kilbaugh; Susan R Rheingold; Lillian Sung; Theoklis E Zaoutis; Robert A Berg; Vinay M Nadkarni; Neal J Thomas; Richard Aplenc
Journal:  Pediatr Crit Care Med       Date:  2014-02       Impact factor: 3.624

9.  Hospital charges and length of stay associated with septicemia among children hospitalized for leukemia treatment in the United States.

Authors:  Veerajalandhar Allareddy; Sankeerth Rampa; Veerasathpurush Allareddy
Journal:  World J Pediatr       Date:  2012-08-12       Impact factor: 2.764

Review 10.  Pathophysiology and management of septic acute kidney injury.

Authors:  Adam Romanovsky; Catherine Morgan; Sean M Bagshaw
Journal:  Pediatr Nephrol       Date:  2013-02-12       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.